In the quest to understand human health and disease, the liver remains one of the most challenging frontiers. Often described as the body’s primary chemical processing plant, the liver performs hundreds of vital functions, from detoxifying the blood to producing the proteins necessary for clotting. However, its immense functional capacity is inextricably linked to its highly specialized and intricate architecture—a structure that has, until now, proven notoriously difficult to replicate in a laboratory setting.
A significant leap forward in this field has been achieved by a collaborative team of researchers led by the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, Germany. In a study published in the prestigious journal Nature, scientists have successfully engineered a next-generation organoid model known as a "periportal assembloid." This model for the first time reconstructs the liver’s periportal region by integrating three distinct types of liver cells, offering a sophisticated new tool for studying liver injury, fibrosis, and the underlying mechanisms of biliary diseases.
The development represents a major evolution in tissue engineering. While traditional organoids—miniature, simplified versions of organs grown in a dish—have provided valuable insights into cellular behavior, they have historically lacked the structural complexity required to simulate how different cell types work together to facilitate essential processes like bile transport. By successfully mimicking the "plumbing" of the liver, this new assembloid model opens the door to more accurate drug testing and a deeper understanding of how liver diseases progress at a cellular level.
The Architectural Challenge of the Human Liver
To understand the significance of this breakthrough, one must first look at the unique and demanding structure of the liver. The organ is organized into functional units where hepatocytes, the primary functional cells of the liver, are arranged in a way that allows them to interact simultaneously with the blood supply and the biliary system.
Hepatocytes are responsible for secreting bile, a digestive fluid essential for the breakdown of fats. They release this bile into incredibly small, delicate channels known as bile canaliculi. These tiny conduits form a vast network that eventually drains into the bile ducts located in the liver’s periportal region. When this intricate drainage system is disrupted—whether through genetic defects, autoimmune issues, or physical blockages—it leads to cholestatic liver injury. This condition causes bile to back up, leading to toxic accumulation, inflammation, and eventually, the scarring known as biliary fibrosis.
For decades, the investigation of these diseases has been hampered by a lack of representative models. Standard laboratory models, such as two-dimensional (2D) cell cultures, fail to capture the three-dimensional (3D) spatial relationships between cells. Even more recent tissue-derived liver organoids have generally been limited to a single cell type. These "monocultures" cannot replicate the complex cellular composition or the specific tissue architecture of the periportal region, leaving a significant gap in the ability of researchers to observe how different cells communicate during the onset of disease.
Building the "Periportal Assembloid"
The research group of Meritxell Huch, a director at the MPI-CBG, has been working to bridge this gap for several years. In a foundational study conducted in 2021, Huch’s team developed a liver organoid consisting of two cell types: cholangiocytes (cells that line the bile ducts) and mesenchymal cells (connective tissue cells). While that model was a step forward in understanding cell-to-cell interactions, it lacked the most critical component: the hepatocytes that make up the vast majority of the liver’s mass and perform its primary metabolic functions.
In the current study, Huch and her colleagues, including fellow MPI-CBG directors Marino Zerial and Heather Harrington, took a "LEGO-like" approach to bioengineering. They set out to build a more complete model by assembling three key cell types in a precise, stepwise fashion.
"To achieve our goal, we first created organoids only consisting of hepatocytes that formed working bile channels and maintained key features of real hepatocytes in the tissue," explains Aleksandra Sljukic, one of the study’s first authors and a doctoral student in the Huch group. Once these functional hepatocyte units were established, the researchers added cholangiocytes and fibroblast (mesenchymal) cells to the mix.
The result was the "periportal assembloid." Unlike previous models, these assembloids demonstrated the ability to consistently drain bile from the internal canaliculi into the bile duct, mirroring the physiological flow found in a living liver. This functional validation proved that the researchers had successfully recapitulated the accurate tissue architecture necessary for the liver’s drainage system to operate.
A New Lens for Liver Disease and Fibrosis
The ability to create a functional, multi-cellular model has immediate implications for disease modeling. The research team focused specifically on the periportal region because of its central role in bile transport and its vulnerability in many liver pathologies.
"We chose this region in particular since it plays a key role in bile transport and is often disrupted in liver diseases when the connection of cells responsible for bile transport is blocked," says Anna Dowbaj, a postdoctoral researcher in the Huch group and first author of the study. Dowbaj, who will transition to an assistant professor role at the Technical University of Munich (TUM) in 2025, emphasizes that the model allows researchers to see exactly how different cell types contribute to the breakdown of this system.
One of the most striking applications of the assembloid was the simulation of liver fibrosis. By manipulating the number of mesenchymal cells within the model, the scientists were able to trigger a pathological response similar to the scarring seen in human patients. Furthermore, the modular nature of the assembloid allows for "mix-and-match" experiments. Researchers can combine healthy cells with mutated cells, or use gene-editing tools to turn off specific genes in one cell type while leaving others untouched. This level of precision enables scientists to pinpoint which specific cell interaction is responsible for a disease state, a task that is nearly impossible in complex animal models or simplified 2D cultures.
To further refine the model, the team collaborated with Heather Harrington and her colleagues at the University of Oxford. Using topological data analysis—a branch of mathematics that looks at the "shape" of data—the researchers were able to classify the various shapes the assembloids took. They discovered that certain structural configurations correlated with better liver function over time, providing a quantitative way to measure the success of their lab-grown tissues.
Vision for the Future of Pharmaceutical Testing
While the current periportal assembloids are a landmark achievement, the researchers acknowledge that there is still work to be done. The current model includes the primary structural and functional cells of the periportal region, but it does not yet incorporate the endothelium (blood vessel lining) or immune cells, both of which play roles in liver health and inflammation.
Nevertheless, the "all-in-one" nature of the model makes it a powerful asset for the future of drug development. Currently, the pharmaceutical industry relies heavily on 2D cell cultures for initial drug screenings. These models are often poor predictors of how a drug will behave in a human body because they lack the 3D architecture and cell-to-cell signaling of real tissue. This discrepancy often leads to drugs failing in late-stage clinical trials due to unforeseen toxicity or lack of efficacy.
Meritxell Huch envisions a future where these assembloids serve as a more reliable bridge between the laboratory and the clinic. "We are excited that we were able to create a periportal assembloid model that combines, for the first time, portal mesenchyme, cholangiocytes, and hepatocytes," Huch says. "Its modular features allow it to be easily studied, handled, and manipulated in the lab."
The ultimate goal is to translate these findings using human-derived cells. If successful, these patient-specific assembloids could be used to test how a particular individual might respond to a drug, ushering in a new era of personalized medicine for liver disease. "Once translated to human cells, it could be a way of moving from 2D models utilized in pharmaceutical screenings to more physiological 3D models to study drug efficacy and toxicity in a more physiologically relevant context," Huch concludes.
As the scientific community continues to move away from animal testing and toward more human-centric models, the development of the periportal assembloid stands as a testament to the power of interdisciplinary collaboration. By combining biology, engineering, and mathematics, the researchers at MPI-CBG have not only built a better model of the liver—they have provided a roadmap for reconstructing the complex beauty of human physiology in a dish.
